The US Food and Drug Administration’s three- to five-year estimate for a rulemaking on lawful use of cannabidiol in dietary supplements rattled a House subcommittee chairwoman already disappointed in the agency’s oversight of the exploding market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?